NZ600640A - Abuse-resistant formulations - Google Patents

Abuse-resistant formulations

Info

Publication number
NZ600640A
NZ600640A NZ600640A NZ60064010A NZ600640A NZ 600640 A NZ600640 A NZ 600640A NZ 600640 A NZ600640 A NZ 600640A NZ 60064010 A NZ60064010 A NZ 60064010A NZ 600640 A NZ600640 A NZ 600640A
Authority
NZ
New Zealand
Prior art keywords
dosage form
abuse
hydromorphone
resistant formulations
sustained
Prior art date
Application number
NZ600640A
Other languages
English (en)
Inventor
Ehab Hamed
Zepeda Manuel A Vega
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of NZ600640A publication Critical patent/NZ600640A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ600640A 2009-12-17 2010-12-16 Abuse-resistant formulations NZ600640A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751509P 2009-12-17 2009-12-17
PCT/US2010/060755 WO2011084593A2 (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Publications (1)

Publication Number Publication Date
NZ600640A true NZ600640A (en) 2014-11-28

Family

ID=43618139

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ600640A NZ600640A (en) 2009-12-17 2010-12-16 Abuse-resistant formulations

Country Status (10)

Country Link
US (2) US20120225122A1 (https=)
EP (1) EP2512456A2 (https=)
JP (1) JP5894717B2 (https=)
CN (1) CN102665694A (https=)
AU (1) AU2010339882B2 (https=)
CA (1) CA2784407A1 (https=)
IL (1) IL219961A (https=)
MX (1) MX348361B (https=)
NZ (1) NZ600640A (https=)
WO (1) WO2011084593A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784336B2 (en) 2005-08-24 2014-07-22 C. R. Bard, Inc. Stylet apparatuses and methods of manufacture
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CN101925333B (zh) 2007-11-26 2014-02-12 C·R·巴德股份有限公司 用于脉管系统内的导管放置的集成系统
US8849382B2 (en) 2007-11-26 2014-09-30 C. R. Bard, Inc. Apparatus and display methods relating to intravascular placement of a catheter
US10751509B2 (en) 2007-11-26 2020-08-25 C. R. Bard, Inc. Iconic representations for guidance of an indwelling medical device
US8781555B2 (en) 2007-11-26 2014-07-15 C. R. Bard, Inc. System for placement of a catheter including a signal-generating stylet
US10449330B2 (en) 2007-11-26 2019-10-22 C. R. Bard, Inc. Magnetic element-equipped needle assemblies
US10524691B2 (en) 2007-11-26 2020-01-07 C. R. Bard, Inc. Needle assembly including an aligned magnetic element
US9649048B2 (en) 2007-11-26 2017-05-16 C. R. Bard, Inc. Systems and methods for breaching a sterile field for intravascular placement of a catheter
US9521961B2 (en) 2007-11-26 2016-12-20 C. R. Bard, Inc. Systems and methods for guiding a medical instrument
US8478382B2 (en) 2008-02-11 2013-07-02 C. R. Bard, Inc. Systems and methods for positioning a catheter
US9901714B2 (en) 2008-08-22 2018-02-27 C. R. Bard, Inc. Catheter assembly including ECG sensor and magnetic assemblies
US8437833B2 (en) 2008-10-07 2013-05-07 Bard Access Systems, Inc. Percutaneous magnetic gastrostomy
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
RU2549998C2 (ru) 2009-06-12 2015-05-10 Бард Аксесс Системс, Инк. Способ позиционирования конца катетера
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011019760A2 (en) 2009-08-10 2011-02-17 Romedex International Srl Devices and methods for endovascular electrography
CN102665541B (zh) 2009-09-29 2016-01-13 C·R·巴德股份有限公司 与用于导管的血管内放置的设备一起使用的探针
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
WO2011097312A1 (en) 2010-02-02 2011-08-11 C.R. Bard, Inc. Apparatus and method for catheter navigation and tip location
CA3054544C (en) 2010-05-28 2022-01-04 C.R. Bard, Inc. Apparatus for use with needle insertion guidance system
EP2912999B1 (en) 2010-05-28 2022-06-29 C. R. Bard, Inc. Apparatus for use with needle insertion guidance system
JP2013535301A (ja) 2010-08-09 2013-09-12 シー・アール・バード・インコーポレーテッド 超音波プローブヘッド用支持・カバー構造
BR112013002431B1 (pt) 2010-08-20 2021-06-29 C.R. Bard, Inc Sistema para a reconfirmação da posição de um cateter no interior de um paciente
CN103189009B (zh) 2010-10-29 2016-09-07 C·R·巴德股份有限公司 医疗设备的生物阻抗辅助放置
AU2012278809B2 (en) 2011-07-06 2016-09-29 C.R. Bard, Inc. Needle length determination and calibration for insertion guidance system
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
WO2013070775A1 (en) 2011-11-07 2013-05-16 C.R. Bard, Inc Ruggedized ultrasound hydrogel insert
WO2013158638A1 (en) * 2012-04-17 2013-10-24 Mylan, Inc. Stable dosage forms of skeletal muscle relaxants with extended release coating
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
CA2883077C (en) * 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CN105979868B (zh) 2014-02-06 2020-03-10 C·R·巴德股份有限公司 用于血管内装置的导向和放置的系统和方法
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10973584B2 (en) 2015-01-19 2021-04-13 Bard Access Systems, Inc. Device and method for vascular access
WO2016210325A1 (en) 2015-06-26 2016-12-29 C.R. Bard, Inc. Connector interface for ecg-based catheter positioning system
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11000207B2 (en) 2016-01-29 2021-05-11 C. R. Bard, Inc. Multiple coil system for tracking a medical device
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN112867443B (zh) 2018-10-16 2024-04-26 巴德阿克塞斯系统股份有限公司 用于建立电连接的安全装备连接系统及其方法
MX2021005888A (es) 2018-11-26 2021-06-23 Procter & Gamble Preparacion farmaceutica solida que contiene acido lipoico y uso de esta.
US12544101B2 (en) 2019-01-30 2026-02-10 Bard Access Systems, Inc. Systems and methods for tracking medical devices
JP7582961B2 (ja) 2019-11-20 2024-11-13 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2572491A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
ES2611794T3 (es) * 2007-09-13 2017-05-10 Cima Labs Inc. Formulación de medicamentos resistentes al abuso
PL2057984T3 (pl) * 2007-11-09 2010-05-31 Acino Pharma Ag Tabletki z hydromorfonem o przedłużonym uwalnianiu
CA2798702A1 (en) * 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms

Also Published As

Publication number Publication date
CA2784407A1 (en) 2011-07-14
US9474721B2 (en) 2016-10-25
US20140294953A1 (en) 2014-10-02
JP5894717B2 (ja) 2016-03-30
WO2011084593A2 (en) 2011-07-14
MX2012006829A (es) 2012-07-10
AU2010339882B2 (en) 2016-10-27
MX348361B (es) 2017-06-07
EP2512456A2 (en) 2012-10-24
WO2011084593A3 (en) 2012-03-29
AU2010339882A1 (en) 2012-07-05
CN102665694A (zh) 2012-09-12
IL219961A (en) 2017-06-29
IL219961A0 (en) 2012-07-31
JP2013514386A (ja) 2013-04-25
US20120225122A1 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
NZ600640A (en) Abuse-resistant formulations
MX347753B (es) Formulaciones resistentes al abuso.
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
MX2012013021A (es) Formulaciones resistentes a alcohol.
WO2008135527A3 (en) Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
NZ610701A (en) Once daily formulation of lacosamide
MX2007009162A (es) Formas de dosis rsistente al alcohol.
MX343358B (es) Tabletas de acetato de ulipristal.
MX346335B (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
MX2007004736A (es) Composicion farmaceutica que comprende diclofenaco.
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
WO2011104652A3 (en) Veterinary compositions
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
UA103179C2 (ru) Фармацевтическая композиция, которая содержит эзетимиб
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2009069151A3 (en) Controlled release composition
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
WO2009019662A3 (en) Oral metaxalone compositions
HK1174276A (en) Abuse-resistant formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 DEC 2017 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS

Effective date: 20150305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2018 BY DENNEMEYER + CO

Effective date: 20171122

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 DEC 2019 BY DENNEMEYER+CO

Effective date: 20181123

LAPS Patent lapsed